New Drugs of 2012: A Concise Overview of the NMEs and Trends for Innovative Brand Market in the United States

DOI:

https://doi.org/10.37285/ijpsn.2013.6.2.1

Authors

  • D Samba Reddy

Abstract

Thirty-nine (39) new drugs have been approved by the U.S. FDA in 2012, a record highest number of approvals since 1996. The record is a sign that pharma companies are poised to tap recent advances from genomics and proteomics. This list includes novel new drugs, known as new molecular entities (NMEs), biologics and new products. Many life-saving drugs are approved for marketing. The list includes a total of 10 drugs for cancer treatment, and nearly a quarter of those approved in 2012 had orphan drug status.  Among the breakthrough drugs approved in 2012 were ivacaftor (cystic fibrosis), vasmodegib (skin cancer), HPC-C (human cord blood product), ruxolitinib (myelofibrosis) and a new combination drug to treat HIV. In addition,  several unique products were approved for the treatment of macular degeneration, chronic weight management, overactive bladder, actinic keratosis, erectile dysfunction, glaucoma, respiratory distress syndrome, and COPD. The approval of 39 drugs in 2012 underscores a robust success rate and confirms that innovation is once again beginning to pay off. In the existing climate of reduced revenues in the face of generic competitions, the future and survival of big companies rests heavily on their unique niche products. It is apparent that big Pharma and a growing number of emerging Biotechs alike have focused their attention on developing new NMEs for rare diseases. In 2012, the length of the FDA’s review is shorter than agencies in other countries. Innovative models adopted for R&D strategies, communications, and new regulatory changes appear to shorten development timelines. Despite record drug approvals, there is bleak scope for blockbusters because most of these drugs have a limited market. The pipeline for blockbusters appears very low. However, there is unmet medical need for new drugs in autism, Alzheimer’s disease and epilepsy. Overall, the new drug approval list unveils unique and reemerging trends indicating that the pharma companies are poised for big growth from new brands approved for marketing for narrow-spectrum indications.  

 

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Biologics, blockbuster drugs, cancer drugs, drug discovery, new drugs, NMEs, pipeline syndrome, preclinical models

Downloads

Published

2013-08-31

How to Cite

1.
Reddy DS. New Drugs of 2012: A Concise Overview of the NMEs and Trends for Innovative Brand Market in the United States. Scopus Indexed [Internet]. 2013 Aug. 31 [cited 2024 Dec. 9];6(2):2009-13. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/614

Issue

Section

Review Articles

References

FDA (2012). FY 2012 Innovative drug approvals. FDA Brochure, December 2012, 1-27.

CDER (2012). Novel new drugs. CDER, FDA Brochure, January 2012, 1-14.

DeRuiter J and Holston PL (2012). New Drug Review 2012. US Pharmacist 37(10): 46-55.

Reddy DS and Woodward R (2004). Ganaxolone: A perspective overview. Drugs Future 29: 227-242.

Mancano MA, Lum JV, Beyzarov E, Whartenby J and Allikas D (2013). New drugs of 2012, Part I & II. Pharmacy Times. February, 1-9.

Mullard A (2011). Reliability of new drug target claims called into question. Nature Rev Drug Discovery 10: 643-644.

Rabasseda X, Dulsat C, Navarro D, Cruces E, Graul AI, Jago C and Tracy M (2013). 2012 in review - Part II: Overcoming the obstacles in the pharma/biotech industry. Drugs Today (Barc) 49(2): 117-43.

Reddy DS (2012). Novel new drug approvals in 2011: A succinct analysis of drug discovery trends in the United Sttes. Int J Pharma Sci Nanotech 5(2): 1661-1665.

Scannell JW, Blanckley A, Helen Boldon H and Warrington B (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Rev Drug Discovery 11: 191-200.

Swinney DC and Anthony J (2011). How were new medicines discovered? Nat Rev Drug Discovery 10: 507-519.

Wickenden A, Priest B and Erdemli G (2012). Ion channel drug discovery: challenges and future directions. Future Med Chem 4: 661-679.